If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
=== Violent or major crime === Typically, cold cases are violent and other major felony crimes, such as murder and rape, which—unlike unsolved minor crimes—are generally not subject to a statute of limitations. Sometimes disappearances can also be considered cold cases if the victim has not been seen or heard from for some time, such as the case of Natalee Holloway or the Beaumont children.
=== June 2025 military parade and "No Kings" protests === On June 14, the Trump administration held the U.S. Army 250th Anniversary Parade in Washington, D.C., to celebrate the 250th anniversary of the U.S. Army. The parade is estimated to have cost somewhere between $25 and $45 million. In protest, 50501, Indivisible, and other organizations organized No Kings protests in many American cities. Millions attended what was then the largest protest since Trump was re-elected. Two follow up No Kings protests (also referred to as No Kings 2 and No Kings 3) took place across the United States and cities abroad in October 2025 and March 2026. The October protests took place in some 2,700 locations across the country, and drew an estimated 7 million attendees, The March 2026 protests, held in response to the killings of Alex Pretti and Renée Good, as well as the 2026 Minnesota general strike, drew even more participants. The organizers claim the No Kings 3 protests took place in 3,300 locations and drew an estimated eight to nine million protestors, which would make it the largest single-day protest in American history.
== Visual rehabilitation and cataract surgery after RK == The PERK study demonstrated that people who undergo RK continue to drift toward hyperopia ("farsightedness"). Additionally, many of these people have reached the age where presbyopia occurs. Some also develop cataracts. Their vision can still be restored with Epi-LASIK, photorefractive keratectomy, LASIK or phakic lens extraction, or cataract surgery. The corneal curvature has to remeasured and modified by history, central keratometry, or contact lens method. Selecting intraocular lenses for cataract surgery in patients who have undergone any refractive surgery has proven challenging and is associated with decreased accuracy in lens selection. RK is associated with increased inaccuracy compared to other refractive procedures such as LASIK and PRK. This is due to difficulty measuring the corneal curvature of post-RK corneas as well as difficulty identifying an effective lens position using standard lens calculations. Additional methods have been introduced to improve the accuracy of IOL calculations. Multifocal IOL insertion in eyes that have undergone RK have not been associated with good outcomes and are generally not recommended.
Sources: en.wikipedia.org
The major long-term complications of diabetes relate to damage to blood vessels at both macrovascular and microvascular levels. Diabetes doubles the risk of cardiovascular disease, and about 75% of deaths in people with diabetes are due to coronary artery disease. Other macrovascular morbidities include stroke and peripheral artery disease. Microvascular disease affects the eyes, kidneys, and nerves. Damage to the retina, known as diabetic retinopathy, is the most common cause of blindness in people of working age. The eyes can also be affected in other ways, including development of cataract and glaucoma. It is recommended that people with diabetes visit an optometrist or ophthalmologist once a year. Diabetic nephropathy is a major cause of chronic kidney disease, accounting for over 50% of patients on dialysis in the United States. Diabetic neuropathy, damage to nerves, manifests in various ways, including sensory loss, neuropathic pain, and autonomic dysfunction (such as postural hypotension, diarrhea, and erectile dysfunction). Loss of pain sensation predisposes to trauma that can lead to diabetic foot problems (such as ulceration), the most common cause of non-traumatic lower-limb amputation. Hearing loss is another long-term complication associated with diabetes. Based on extensive data and numerous cases of gallstone disease, it appears that a causal link might exist between type 2 diabetes and gallstones. People with diabetes are at a higher risk of developing gallstones compared to those without diabetes.
G. K. Fortescue, ed. (1902). "Bristol". Subject Index of the Modern Works Added to the Library of the British Museum in the Years 1881–1900. London: The Trustees. pp. 6 v. hdl:2027/uc1.b5107011. Robert Donald, ed. (1908). "Bristol". Municipal Year Book of the United Kingdom for 1908. London: Edward Lloyd. hdl:2027/nyp.33433081995593. "Bristol (England)" . Encyclopædia Britannica. Vol. 4 (11th ed.). 1911. pp. 579–582. Published in the 21st century
=== Brand names === Dutasteride is sold primarily under the brand name Avodart, but also in combination with tamsulosin under the brand names Combodart, Duodart, and Jalyn. Dutasteride is also available in India in combination with alfuzosin under the brand names Alfusin-D and Dutalfa.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。